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Abstract
Background: Dimethyl fumarate (DMF), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, has been
proven effective for the systemic treatment of multiple sclerosis. The aim of this study is to evaluate the
anti-inflammatory effects of Nrf2 activators on human renal mesangial cells (HRMCs) and the development of lupus
nephritis (LN) in mice.
Methods: To assess Nrf2 activation in vitro, HRMCs were treated with safe doses of Nrf2 activators and
prednisolone. The expression levels of Nrf2 and its target genes were measured using quantitative reverse
transcription PCR and enzyme-linked immunosorbent assay. The anti-inflammatory effects of these compounds
were assessed by measuring tumor necrosis factor alpha-induced cytokine secretion. Experimental LN was induced
in female BALB/c mice by a single intraperitoneal injection of pristane. The urine albumin-to-creatinine ratio was
measured at 20 weeks after injection. Pathological changes as well as protein and mRNA expression levels were
assessed in the kidney obtained at the experimental end point. Oral administration of DMF or prednisolone to
these mice was initiated after pristane injection.
Results: Nrf2 activators such as sulforaphane and DMF showed anti-inflammatory effects in HRMCs, whereas
glucocorticoid (prednisolone) showed partial effects. Moreover, DMF ameliorated the development of kidney
diseases in pristane-induced LN mice, whereas glucocorticoid had no effect.
Conclusions: Nrf2 activators showed stronger anti-inflammatory and organ-protective effects than glucocorticoid in
the kidney. Thus, Nrf2 activators are potential therapeutic targets in glucocorticoid-resistant LN in humans.
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Background
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by inflammation in different organ sys-
tems and immunologic abnormalities, such as presence of
autoreactive T cells and hyperactive B cells producing auto-
antibodies [1]. Approximately 25–50 % of SLE patients de-
velop lupus nephritis (LN), which is initiated by the
deposition of immune complexes within the renal paren-
chyma leading to complement activation, mesangial expan-
sion, and induction of inflammatory and fibrotic processes,
resulting in glomerulonephritis and progressive renal
dysfunction [2]. LN patients are often treated with strong
immunosuppressive regimens, including cytotoxic drugs,
antimalarial compounds, immunophilin targeting agents,
and glucocorticoids [3]. In addition, the effect of these
therapeutic medications on LN has been determined by the
histologic diagnosis of glomerulonephritis [3]. The treat-
ments can transiently reduce disease activity, but often do
not induce remission or prevent end organ damage.
The polymorphisms in the nuclear factor erythroid 2-
related factor 2 (Nrf2) genes appear to confer a risk for de-
veloping LN [4]. Moreover, Nrf2 deficiency leads to the
development of lupus-like autoimmune nephritis in aged
female mice [5], indicating that Nrf2 plays a crucial role in
the development of LN in both human and mice. Nrf2 is a
redox-sensitive transcription factor that regulates the
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expression of antioxidant response element (ARE)-
dependent genes, such as those encoding antioxidant and
detoxifying enzymes like heme oxygenase-1 (HO-1) and
NAD(P)H:quinone oxidoreductase 1 (NQO1) [6]. Under
normal conditions, Nrf2 is retained in the cytoplasm in a
“silent” form by its repressor protein, Kelch-like ECH-
associated protein 1 (Keap1), which contains a subset of
reactive cysteine residues. Oxidative stress or environmen-
tal stimuli modifies the cysteine residues of Keap1, thus
enabling translocation of Nrf2 to the nucleus where it
binds to the ARE [6]. The activation of Nrf2 leads not only
to organ-protective effects but also to anti-inflammatory
effects by inhibition of nuclear factor (NF)-kB activation.
[7]. In a previous study, antioxidant response of Nrf2 and
NQO1, which functions in the downstream of Nrf2, was
demonstrated in the kidney of patients with LN; however,
it was not determined whether the response modified the
disease activity or not [8].
Small-molecule compounds such as sulforaphane and
dimethyl fumarate (DMF) have been reported as the clin-
ically used Nrf2 activators [9, 10]. Sulforaphane, an orga-
nosulfur compound found in broccoli sprouts and other
cruciferous vegetables, has potent anti-inflammatory or
anticancer activities, and has been clinically used as a
dietary supplement [11]. It inhibited proinflammatory
cytokine production in vitro in lipopolysaccharide (LPS)-
stimulated monocytes [12] and tumor necrosis factor
alpha (TNF-α)-stimulated synoviocytes [13]. Furthermore,
sulforaphane improved the development of experimental
autoimmune encephalomyelitis (EAE) [14] and alleviated
type II collagen-induced arthritis [15] and dextran sodium
sulfate-induced acute colitis [16] in mice. In contrast,
DMF is the main active ingredient of fumaric acid esters
(FAEs) and has been approved in Germany as Fumaderm®
for the systemic treatment of psoriasis [17]. It demon-
strated anti-inflammatory activity both in vitro and in
vivo. DMF inhibited proinflammatory cytokine production
in TNF-α-stimulated human umbilical vein endothelial
cells [18] and LPS/interferon gamma (IFNγ)-stimulated
peripheral blood mononuclear cells (PBMCs) [19] by inhi-
biting either the activation or translocation of NF-kB in
vitro. Moreover, DMF ameliorated the development of
mouse EAE [10]. The efficacy of oral DMF in the treat-
ment of relapsing–remitting multiple sclerosis (RRMS)
has been proven in two phase III studies: DEFINE (Deter-
mination of the Efficacy and Safety of Oral Fumarate in
relapsing–remitting multiple sclerosis) [20] and CON-
FIRM (Comparator and an Oral Fumarate in relapsing–
remitting multiple sclerosis) [21]. In 2013, DMF was ap-
proved by the US Food and Drug Administration (FDA)
as first-line therapy for RRMS patients [22]. In-vivo stud-
ies in psoriasis patients showed that DMF reduced the de-
velopment of psoriasis [23], and the clinical efficacy of
DMF is being explored in a phase III trial (ClinicalTrials.
gov NCT01815723). As already described, the effect of the
clinically used Nrf2 activators such as sulforaphane and
DMF on the development of various chronic inflamma-
tory diseases has been evaluated. However, there are no
reports about the effects of these compounds on the de-
velopment of human LN.
Here, we investigated the effects of clinically used Nrf2
activators on renal functions both in vitro and in vivo.
To assess the in-vitro functions, human renal mesangial
cells (HRMCs) were used. Mesangial cells typically have
physiological functions including phagocytosis, synthesis
of the mesangial extracellular matrix, and control of
glomerular hemodynamics via mesangial cell contraction
[24]. In response to immunological, toxic, ischemic, or
mechanical injury, mesangial cells produce chemokines
or cytokines that selectively induce inflammatory cell
migration and activation at the site of injury [25].
Pristane-injected mice were treated with DMF, an Nrf2
activator with ensured clinical safety [22], to evaluate its
in-vivo effects on the development of LN. Pristane is a
natural hydrocarbon oil, also called TMPD (2,6,10,14-
tetramethylpentadecane). Pristane-induced LN is asso-
ciated with hypergammaglobulinemia, lupus-related
autoantibody production, and immune complex-mediated
glomerulonephritis, and resembles human LN [26]. In this
model, Nrf2-deficient mice developed a greater degree of
renal damage [8]. We examined possible therapy with
Nrf2 activators both in vitro and in vivo, and glucocortic-




DMF (BG-12), sulforaphane, and prednisolone were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). For
the cellular functional assay, these compounds were dis-
solved in dimethylsulfoxide (DMSO; Nacalai Tesque,
Kyoto, Japan) and stored in aliquots at –20 °C. For the
animal model, DMF and prednisolone were suspended
in 0.5 % methylcellulose as vehicle.
Antibodies and flow cytometric analysis
Monoclonal antibodies (mAbs) used were PE-conjugated
anti-human CD120b (hTNFR-M1), biotin-conjugated
anti-human CD120a (MABTNFR1-B1), and isotype-
matching control mAb. Allophycocyanin-conjugated
streptavidin was used for staining biotin antibodies. All
of these were purchased from BD Biosciences (San Jose,
CA, USA). For Fc receptor blocking, we used FcR Block-
ing Reagent (Miltenyi Biotech, Auburn, CA, USA). Cell
surface staining was performed according to standard
techniques, and flow cytometry was performed with a
FACSCalibur flow cytometer and analyzed using Cell-
Quest™ Pro software (BD Biosciences).
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Cell culture
HRMCs were purchased from ScienCell Research La-
boratories (Carlsbad, CA, USA), and maintained in the
Mesangial cell medium (ScienCell Research Laborator-
ies) in a humidified atmosphere containing 5 % CO2 at
37 °C. HRMCs were used between passages 3 and 6.
Cellular treatments
HRMCs were plated in 96-well poly-L-lysine-coated plates
(BD Biosciences) at a density of 1.5 × 104 cells per well.
Nrf2 activators, DMF and sulforaphane, or prednisolone
were added to the culture media, and DMSO at a final
concentration of 0.1 % in culture medium was used as the
vehicle control. To evaluate the cytotoxicity of the com-
pounds, the CellTiter-Glo luminescent cell viability assay
was performed according to the manufacturer’s instructions
(Promega, Madison, WI, USA). In experiments examining
the anti-inflammatory effects of Nrf2 activators or prednis-
olone on TNF-α-induced monocyte chemoattractant
protein-1 (MCP-1) or interleukin-6 (IL-6) production, these
compounds were added 1 hour before the addition of TNF-
α (R&D Systems, Minneapolis, MN, USA). Cells were
cultured for 18 hours, and then the supernatants were col-
lected and stored at –80 °C until they were assayed.
Measurement of NF-kB or Nrf2 transcriptional activity
The activity of nuclear NF-kB or Nrf2 was determined
using TransAM transcriptional factor assaying kits for
NF-kB p65 or Nrf2 according to the manufacturer’s in-
structions (Active Motif, Carlsbad, CA, USA). The nu-
clear extract kit was from Active Motif. NF-kB p65
protein (Active Motif ) or Nrf2 protein (Abnova, Taipei,
Taiwan) was used as the standard in each kit.
Protein quantification
Cells were rinsed with phosphate-buffered saline (PBS)
and solubilized in lysis buffer, which was PBS containing 1
mM ethylenediaminetetraacetic acid, 0.5 % Triton X-100,
10 μg/ml leupeptin, 10 μg/ml pepstatin, 100 μM phenyl-
methanesulfonyl fluoride, and 3 μg/ml aprotinin (all from
Sigma-Aldrich). Intracellular HO-1 (R&D Systems) and
NQO1 (Cusabio, Wuhan, China) expressions were de-
tected using enzyme-linked immunosorbent assay (ELISA)
kits according to the manufacturers’ instructions. The
total protein level in the cell lysate was detected using the
Pierce™ BCA Protein Assay kit according to the manufac-
turer’s instructions (Thermo Fisher Scientific, Waltham,
MA, USA). The amount of MCP-1 and IL-6 released into
the supernatants of the cultured cells was determined
using ELISA kits (R&D Systems).
RNA isolation and real-time PCR
RNAs were isolated from HRMCs using the GenElute
mammalian total RNA kit (Sigma-Aldrich). Quantitative
reverse transcription PCR (RT-PCR) was performed using
the RNA-to-CT 1-step kit (Thermo Fisher Scientific) and
the ABI PRISM 7900HT system (Thermo Fisher Scien-
tific). The primers (HO-1: Hs01110250_m1, NQO1:
Hs00168547_m1, glucocorticoid receptor alpha (GRα):
Hs00230818_m1, GRβ: Hs00354508_m1, glyceraldehyde
3-phosphate dehydrogenase (GAPDH): Hs02758991_g1)
were from Thermo Fisher Scientific. The comparative
cycle time (CT) was used to normalize transcripts to
GAPDH.
Mice
Female BALB/c mice were obtained from SLC (Shizuoka,
Japan) and maintained under specific pathogen-free con-
ditions in the Animal Research Institute of the Tohoku
University Graduate School of Medicine, Sendai, Japan.
All experiments performed in this study conformed to the
ethical guidelines of Tohoku University regarding animal
experimentation.
Determination of the effect of medications on pristane-
induced nephritis
Female BALB/c mice were injected intraperitoneally
with either 0.5 ml pristane (Sigma-Aldrich) or PBS at 7
weeks of age. The medications were administered daily
by oral gavage from the starting day until the experi-
mental end point (for 20 weeks), as described previously
[27]. Each treatment group consisted of five to seven
mice: vehicle alone, 75 mg/kg body weight (bw) DMF, or
2 mg/kg bw prednisolone. The DMF dose was decided
based on the recommended human dose of 480 mg/day
for multiple sclerosis (MS) [22]. Conversely, the dose of
prednisolone was equal to that in the previous reports
[28, 29]. At 20 weeks after injection, urine was collected
from these mice for 24 hours using the metabolic cages.
After killing the mice under anesthesia, the kidneys were
removed and frozen for protein and RNA extraction, or
fixed for histology analysis. The concentration of urine
albumin was measured by ELISA (Shibayagi, Gunma,
Japan) and urine creatinine was measured using Liqui-
tech creatinine PAP II (Roche Diagnostics, Basel,
Switzerland) and an automatic analyzer (Hitachi 7180;
Hitachi High-Technologies, Tokyo, Japan). The urine
albumin-to-creatinine ratio (uACR) was expressed as
milligrams of albumin per gram of creatinine.
Serum samples were stored at –80 °C until they were
assayed. ELISA kits were used to measure the autoantibody
titers, which are anti-double strand (ds) DNA (Shibayagi)
and anti-nuclear ribonucleoprotein (nRNP) antibody
(Alpha Diagnostic, San Antonio, TX, USA).
The kidneys were homogenized in the lysis buffer as
already described and both MCP-1 (R&D Systems) and
HO-1 (Takara Bio, Shiga, Japan) levels in the kidney
were measured by ELISA kit. The isolation of RNAs
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from the kidney and the quantitative RT-PCR were
performed as already described. Oligonucleotide
primers were purchased from Thermo Fisher Scientific:
Mm00516005_m1 for HO-1, Mm01253561_m1 for
NQO1, Mm00441242_m1 for MCP-1, Mm00446190_m1
for IL-6, Mm00443258_m1 for TNF-α, Mm01256744_m1
for fibronectin (Fn1), Mm01178820_m1 for tumor growth
factor beta 1 (TGF-β1), and Mm99999915_g1 for
GAPDH.
Pathological evaluation of LN
The kidneys were fixed in 10 % formalin in 0.01 M phos-
phate buffer (pH 7.2) and embedded in paraffin wax. Tissue
sections were stained with periodic acid–Schiffs (PAS) and
used for evaluations. The kidneys were scored by histo-
logical criteria as follows: 0 = positive staining in <25 % of
glomerular cross-section, 1 = positive staining in 25–50 %
of glomerular cross-section, 2 = positive staining in 50–75
% of glomerular cross-section, and 3 = positive staining
in >75 % of glomerular cross-section. At least 40 glom-
eruli per animal were assessed to determine the average
score. The scoring systems of histology were determined
by a pathologist (MO) and a cytologist (HT) blinded to
the treatment.
Statistical analyses
The significance of average differences among multiple
groups was evaluated by the Dunnett’s parametric or
nonparametric test. p < 0.05 was considered significant.
Results
Upregulation of HO-1 and NQO1 expression in HRMCs by
Nrf2 activators
As shown in Fig. 1a, Nrf2 activators such as sulforaph-
ane and DMF induced the binding of Nrf2 to immortal-
ized consensus ARE in HRMCs. Moreover, the Nrf2
activators upregulated the transcription of HO-1 and
NQO1, which are the target genes of Nrf2, in a time-
dependent and dose-dependent manner at the nontoxic
doses (Fig. 1b, c). In HRMCs, Nrf2 activators also signifi-
cantly increased intracellular HO-1 and NQO1 protein
levels 18 hours after the addition of compounds in a
dose-dependent manner (Fig. 1d, e).
Inhibition of the production of MCP-1 and IL-6 by Nrf2
activators
FACS analysis revealed the expression of CD120a
(TNFR1) and CD120b (TNFR2) on the cell surface of
HRMCs (data not shown). The HRMCs secreted MCP-1
or IL-6 after TNF-α stimulation in a dose-dependent
manner (data not shown). To investigate the anti-
inflammatory effects of the test compounds, the inhibition
of MCP-1 and IL-6 production in TNF-α-stimulated
HRMCs was examined. As shown in Fig. 2a, b, Nrf2 acti-
vators such as sulforaphane and DMF inhibited the pro-
duction of MCP-1 and IL-6 in a dose-dependent manner.
On the contrary, surprisingly, prednisolone showed very
less inhibition even at the maximum dose of 100 μM
(Fig. 2a, b). The inhibitory concentrations (IC50) of test
compounds for MCP-1 and IL-6 production are presented
in Table 1. To determine whether NF-kB is involved in
Nrf2 pathway, the effects of Nrf2 activators on TNF-α-
induced NF-kB DNA binding were examined in terms of
NF-kB activation. Although the Nrf2 activators, sulforaph-
ane and DMF, suppressed TNF-α-induced p65 DNA bind-
ing, prednisolone did not suppress the binding even at the
maximum nontoxic dose (Fig. 2c). Taken together, these
results suggest that activating the Nrf2 pathway with sul-
foraphane or DMF inhibited the TNF-α-mediated proin-
flammatory responses in HRMCs.
To investigate the cause of glucocorticoid insensitivity,
the alteration of mRNA expression of GRα (Fig. 2d) and
GRβ (Fig. 2e) by prednisolone treatment under TNF-α
stimulation was examined. GRα functions as a gluco-
corticoid-dependent transcription factor, whereas GRβ
acts as a dominant negative inhibitor of GRα in human
cells [30]. The exposure of HRMCs to prednisolone up-
regulated GRβ in a dose-dependent manner (Fig. 2e). On
the contrary, GRα mRNA expression did not appear to be
altered significantly in the cells (Fig. 2d), suggesting that
the increase in GRβ expression contributes to the gluco-
corticoid insensitivity in HRMCs.
Amelioration of kidney disease as manifested by reduced
proteinuria and glomerulonephritis in pristane-injected
mice treated with DMF
To explore the effect of Nrf2 activator on the progres-
sion of LN, a pristane-induced murine model was used.
(See figure on previous page.)
Fig. 1 Sulforaphane and DMF induced Nrf2 activation in HRMCs. (a) Expression of active Nrf2 in HRMCs. Cells were treated with sulforaphane or
DMF, and after 6 hours the nuclear lysates were prepared and the level of active nuclear Nrf2 binding to DNA was measured using ELISA. Results
are shown as the ratio of Nrf2 to total protein. (b, c) mRNA levels of HO-1 and NQO1 expressions. HO-1 (b) and NQO1 (c) levels were determined
using quantitative RT-PCR at 2 (white bars), 4 (gray bars), and 8 (black bars) hours after the stimulation. Data presented are relative mRNA level
normalized to GAPDH. (d, e) HO-1 and NQO1 protein expression. Intracellular HO-1 (d) and NQO1 (e) concentrations were measured by ELISA 18
hours after the stimulation. Results are shown as the individual protein level to total protein (mean ± SD of three independent experiments).
*p < 0.05, **p < 0.01 by Dunnett’s parametric test performed versus DMSO-stimulated group (–). DMF dimethyl fumarate, HO-1 heme oxygenase-1,
NQO1 NAD(P)H:quinone oxidoreductase 1, Nrf2 nuclear factor erythroid 2-related factor 2
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Fig. 2 Sulforaphane and DMF showed strong anti-inflammatory effects, whereas prednisolone showed slight effects in HRMCs. (a, b) Effect of
these compounds on inflammatory cytokine production in TNF-α-stimulated HRMCs. Cells were incubated with the nontoxic doses of DMF (open
circles), sulforaphane (gray circles), or prednisolone (black circles) prior to TNF-α stimulation. The concentrations of MCP-1 (a) and IL-6 (b) in the
supernatant were determined by ELISA. Results are shown as the % of TNF-α-stimulated (control) groups (mean ± SD of three independent experiments).
(c) Effect of these compounds on NF-kB activation in TNF-α-stimulated HRMCs. Results are shown as the % of TNF-α-stimulated (control) groups (mean ±
SD of three independent experiments). **p< 0.01 by Dunnett’s parametric test performed versus control groups. (d, e) mRNA levels of GRα and GRβ
expression by these compounds exposure under TNF-α stimulation. GRα (d) and GRβ (e) levels were determined using quantitative RT-PCR 18 hours after
the stimulation. Data presented are relative mRNA level normalized to GAPDH. Results are shown as mean ± SD of three independent experiments. *p<
0.05, **p< 0.01 by Dunnett’s parametric test performed versus unstimulated group (–). DMF dimethyl fumarate, GR glucocorticoid receptor, IL-6 interleukin-6,
MCP-1 monocyte chemoattractant protein-1, NF nuclear factor, TNF-α tumor necrosis factor alpha
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Female BALB/c mice were treated daily by oral gavage
with either vehicle only, 75 mg/kg bw DMF, or 2 mg/kg
bw prednisolone after intraperitoneal injection of pris-
tane. It has been established that, after oral intake, one
part of DMF is converted in the small intestinal mucosa
to monomethyl fumarate (MMF), and the other part is
absorbed by the tissues followed by conjugation to gluta-
thione [31]. Thus, both DMF and MMF play the role of
Nrf2 activators in vivo following DMF treatment, as de-
scribed previously [32]. The DMF dose was decided
based on the recommended human dose for MS, which
is calculated using plasma MMF exposure (area under
the blood concentration–time curve) according to that
Table 1 Effects of Nrf2 activators and prednisolone on MCP-1
and IL-6 production in TNF-α-stimulated HRMCsa




aConcentrations of 50 % inhibition (IC50) of MCP-1 and IL-6 production were
calculated from sigmoidal inhibition curves presented in Fig. 3. The IC50 values
were obtained from three individuals
DMF dimethyl fumarate, HRMC human renal mesangial cell, IL-6 interleukin-6,
MCP-1 monocyte chemoattractant protein-1, Nrf2 nuclear factor erythroid
2-related factor 2, TNF-α tumor necrosis factor alpha
Fig. 3 Prevention of development of kidney diseases upon administration of DMF in pristane-injected mice. (a–d) Representative microphotograms of
renal tissue obtained from PBS/0.5 % methylcellulose (sham)-treated (a), pristane/0.5 % methylcellulose (vehicle)-treated (b), pristane/DMF-treated (c), and
pristane/prednisolone-treated (d) mice (PAS staining). Scale bar, 200 μm. (e) Glomerulonephritis score of pristane-induced LN of the four groups of mice at
the experimental end point. *p< 0.05 by Dunnett’s nonparametric test performed versus sham-treated group. (f) At 20 weeks after pristane injection, the
urine albumin-to-creatinine ratio (uACR) was measured. **p< 0.01 by Dunnett’s parametric test performed versus sham-treated group. n= 5–7 animals per
group. DMF dimethyl fumarate
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reported by Biogen Inc. [21], whereas the dose of pred-
nisolone was equal to that in the previous reports [28,
29]. All of the vehicle-administered mice (n = 7) devel-
oped LN to varied extent. In contrast, none of the DMF-
treated mice (n = 7) presented overt LN. As shown in
Fig. 3a, b, the kidneys obtained from these mice dis-
played histopathological characteristics of class II LN
with mesangial hypercellularity and matrix expansion at
the experimental end point. None of the glomeruli met
histopathological conditions for class III or class IV LN.
These findings largely follow the observations reported
previously in pristane-immunized mice [26]. Micro-
scopic examination revealed that DMF exhibited a re-
markable suppression of renal disease (Fig. 3a–e).
Unexpectedly, the treatment of prednisolone had no
effect on the pathological changes (Fig. 3a–e). Pristane
increased uACR, an indicator of kidney vascular perme-
ability, at 20 weeks after the pristane injection (Fig. 3f ).
DMF ameliorated the renal functions, whereas prednis-
olone did not influence the pathologies (Fig. 3f ). Taken
together, DMF improved the kidney disease as mani-
fested by reduced proteinuria and histopathological
analysis.
Inhibition of the production of serum autoantibodies and
renal inflammatory cytokines in pristane-induced LN
treated with DMF
To explore the in-vivo effects of DMF as an Nrf2 activa-
tor, the expressions of HO-1 and NQO1 were examined
in the kidneys of pristane-injected mice. At the experi-
ment end point, both HO-1 protein (Fig. 4a) and NQO1
transcript (Fig. 4b) significantly increased after DMF
treatment within the kidneys of pristane-immunized
mice. However, the mRNA expression of HO-1 was not
detected (data not shown). Since the kidney samples of
these mice were obtained 24 hours after the last admin-
istration of the compounds, it is possible that the HO-1
transcription had already finished. Pristane increased
serum anti-dsDNA (Fig. 4c) and anti-nRNP (Fig. 4d)
antibodies in mice at 20 weeks post injection, as de-
scribed previously [26]. Moreover, not only DMF but
also prednisolone significantly decreased the serum
levels of anti-dsDNA (Fig. 4c) and anti-nRNP (Fig. 4d)
antibodies compared with the sham group. The results
of protein or mRNA quantification analysis performed
using the whole kidney showed significant increase in
the expression of MCP-1 (Fig. 4e, f ) and IL-6 (Fig. 4g),
which were produced in various cells including renal
cells and infiltrating inflammatory cells, in pristane-
injected mice. Further, the analysis of the kidney samples
from the mice treated with DMF demonstrated a signifi-
cant decrease in the expressions of MCP-1 (Fig. 4e, f )
and IL-6 (Fig. 4g). In contrast, prednisolone treatment
did not change the production in the kidney (Fig. 4e–g).
In addition, the TNF-α level was not influenced by
administration of DMF or prednisolone (Fig. 4h). Fibro-
nectin is a component of the glomerular basement
membrane and mesangial matrix, and accumulates along
with other extracellular matrix constituents in prolifera-
tive LN. The fibronectin expression of the kidney signifi-
cantly increased after pristane injection, as described
previously (Fig. 4i) [8]. However, the expression was sig-
nificantly inhibited by treatment with DMF but not
prednisolone (Fig. 4i), as supported by the histopatho-
logical analysis. TGF-β1, which is a key factor in fibrosis,
also increased in pristane-induced LN (Fig. 4i). Never-
theless, administration of DMF significantly decreased
the expression (Fig. 4j). On the contrary, prednisolone
treatment did not decrease the expression (Fig. 4j).
Taken together, DMF protected against renal damage in
murine LN by both altering the organ-protection path-
way and inhibiting the renal inflammation.
Discussion
Several reports have shown that glucocorticoid can effect-
ively inhibit proinflammatory cytokine or chemokine pro-
duction in human immune cells, including PBMCs or
monocytes [33, 34]. However, glucocorticoid-insensitive
NF-kB activation and proinflammatory cytokine produc-
tion have been demonstrated in some nonimmune human
cells, for example brain cells [35] and airway epithelial
cells [36]. Consistent with the described reports, glu-
cocorticoid (prednisolone) showed only a small effect on
IL-6 (Fig. 3a) and MCP-1 (Fig. 3b) production in TNF-α-
stimulated HRMCs in the present study. The association
of glucocorticoid residence and expression of GRβ, which
is a dominant negative inhibitor of GRα, have been clinic-
ally studied in immune-mediated diseases such as
rheumatoid arthritis [37] and ulcerative colitis [38]. The
present study revealed that the exposure of mesangial cells
to glucocorticoid under inflammatory stimulation in-
creased GRβ expression (Fig. 2e). Taken together, the reac-
tion of human mesangial cells in inflammatory response
may be associated with glucocorticoid-insensitive renal
diseases.
Among the many Nrf2 activators, we selected DMF
that has ensured clinical safety and evaluated its effect in
an in-vivo model. Another Nrf2 activator, bardoxolone
methyl, was developed for the treatment of chronic kid-
ney diseases and type II diabetes mellitus. However, the
phase III BEACON (Bardoxolone Methyl Evaluation in
Patients with Chronic Kidney Disease and Type 2
Diabetes Mellitus: the Occurrence of Renal Events) trial
was terminated owing to severe renal dysfunction and
cardiovascular failure [39]. The safety data observed with
DMF suggest that bardoxolone methyl’s side effects may
be compound specific rather than target related. Bardox-
olone methyl as an Nrf2 activator was expected to be a
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new therapeutic approach for renal diseases. In fact, bar-
doxolone methyl has ameliorated kidney disease in
models of ischemic acute kidney injury [40], and further-
more in genetic lupus mice [41]. The other compounds
which have been shown to activate Nrf2, such as
epigallocatechin-3-gallate [42] or hemin [43], have also
suppressed renal disease in spontaneous lupus mice,
such as NZB/W F1 or MRL/lpr mice.
In the present study, we used pristane-induced LN,
which resembles the pathology of human LN [26], as the
animal model. Pristane treatment of the peritoneal cavity
induced apoptosis of peritoneal cells [44] leading to the
production of autoantibodies, resulting in the develop-
ment of LN. Extranodal lymphoid tissue (also called ter-
tiary lymphoid neogenesis) formed in the peritoneal cavity
[45] and was indicative of the inflammatory lesion in this
pristane-treated model as well as in human LN with tubu-
lointerstitial inflammation [46]. It has been indicated that
chronic inflammatory condition leading to lymphoid neo-
genesis is associated with autoantibody production [47].
There are no histopathological studies on fibrosis of
the kidney in pristane-induced LN. In the present study,
the upregulation of TGF-β1 expression in the kidney of
pristane-injected mice was detected at the experimental
end point (Fig. 4j), suggesting that the fibrosis in the kid-
ney of this model may be caused after LN onset. Pristane
caused arthritis in some strains of mice with characteris-
tics such as synovial hyperplasia, periostitis, and mar-
ginal erosions [48]. The pristane-induced arthritis was
strongly inhibited by treatment with prednisolone (2
mg/kg bw) [49]. However, the present study revealed
that treatment with the same dose of prednisolone did
not inhibit the development of pristane-induced LN
(Figs. 3 and 4), suggesting that the difference in the ef-
fects may be dependent on organ specificity, including
renal cells such as mesangial cells or other nonimmune cells.
Interestingly, different from the strongly glucocorticoid-
sensitive LN in NZB/W F1 [28] or MRL/lpr [29] mice,
pristane-induced LN was observed to be glucocorticoid-
insensitive LN (Fig. 3). Our present findings suggest upregu-
lation of GRβ expression, which remains to be identified
in mice LN models, in nonimmune cells such as mesan-
gial cells.
Although prednisolone inhibited autoantibody produc-
tion, kidney disease was not improved in the mice (Figs. 3
and 4). The clinical trial in human LN has also demon-
strated that the elimination of autoantibodies by plasma-
pheresis was unsuccessful [50]. Furthermore, the results of
another phase III clinical trial—the LUNAR (Lupus
Nephritis Assessment with Rituximab) study—revealed that
the treatment of rituximab to deplete B cells in LN (class
III or class IV) has not resulted in more efficient clinical
improvement compared with conventional therapy, despite
the reduction of serum anti-dsDNA antibody levels [51].
Taken together, it is evident that it is very important for the
therapy against LN to directly prevent the kidney disease
and not inhibit the autoantibody production including the
glomerular deposition of immune complexes.
In conclusion, Nrf2 activators had not only anti-
inflammatory effects but also organ-protective effects on
LN pathology. In other words, targeted Nrf2 drugs may be
more effective than the currently used immunosuppres-
sants. The results of two phase III studies about DMF re-
vealed that there were no cases of renal adverse events
[20, 21] and hence DMF is expected to be a new thera-
peutic approach for LN. Thus, Nrf2 activators such as
DMF, which do not cause serious renal adverse events, are
promising alternatives to glucocorticoids for treating ex-
cessive immunological activation in damaged or inflamed
kidney as well as other inflammatory diseases, such as MS
and psoriasis. Our findings provide useful information for
the possible application of Nrf2 activators for the treat-
ment of glucocorticoid-resistant LN patients.
Conclusions
In this study, we found that Nrf2 activators showed anti-
inflammatory and organ-protective effects in the kidney.
Glucocorticoid (prednisolone) showed only a small effect
on proinflammatory cytokine production in TNF-α-
stimulated HRMCs, whereas Nrf2 activators showed
strong anti-inflammatory effects in the cells. Further-
more, the Nrf2 activator DMF ameliorated the develop-
ment of kidney diseases in pristane-induced LN mice,
whereas glucocorticoid did not have any effect. Thus,
Nrf2 activators are potential therapeutic targets in
glucocorticoid-resistant LN in humans.
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